Company Revenue

The company grew in the low-single digits on a reported basis in the first quarter of 2026 due the cyber...

The company's orthopedic sales grew in the mid-single digits in the first quarter of 2026, driven by BioBrace....

The company grew in the high-single digits during the first quarter of 2026 as it transitions its U.S. sales force....

The company grew in the mid-single-digits on a reported basis for the first quarter of 2026 ahead of its impending...

The company grew in the mid-single digits in 2025 on the strength of its new products and continuing adoption of...

The company grew in the low-single-digits in 2025 as it transitions its distributors and strategically shifts to earnout placements for...

In 2025, the company nearly doubled its prior year sales while significantly reducing lead times and expanding its indications....

The company grew 5% on a pro forma basis in 2025 as it transitions from an M&A cycle to a...

The company grew 25% in 2025 as the clinical distinction among its products drives surgeon adoption and utilization across its...

The company grew over 20% in 2025, grew its surgeon user base by 22% and performed nearly 22,000 procedures....